CytomX Therapeutics is a privately funded and publicly traded company based in the San Francisco Bay Area. It is a clinical stage oncology-focused biopharmaceutical company pioneering in a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.
Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. CytomX's product pipeline includes cancer immunotherapies against clinically-validated targets. CX-072 and CX-188 are PD-L1 targeting Probody therapeutic. CX-2009 is an in-class Probody drug conjugate targeting CD166. All three are owned wholly by CytomX.
The company is also collaborating with other biopharmaceutical companies including AbbVie, Amgen, Bristol-Myers Squibb Company, and ImmunoGen, Inc. BMS-986249 is a CTLA-4 targeting Probody therapeutic partnered with Bristol Myers Squibb. CX-2029 is a DC71 targeting Probody drug conjugate partnered with AbbVie.
All products, except CX-188 are in various Phase 1/2 clinical trial progression. CX-2009 is currently being evaluated in its clinical trial, while CX-2009 and BMS-986249 are enrolling patients for the clinical studies.
Senior VP, Program and Alliance Management
Charles S. Fuchs
Senior VP, Talent and Administrative Operations
Co-Founder & Director
Lloyd A. Rowland, Jr.
Senior VP, General Counsel, Secretary, & Chief Compliance Officer
Chief Medical Officer
Sean A. McCarthy
President & CEO
Senior VP, Process Sciences and Manufacturing Operations
W. Michael Kavanaugh
Chief Scientific Officer & Head of Research and Non-Clinical Development
Documentaries, videos and podcasts